Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

NCT00765817 · Completed

Last updated 2026-05-28

This clinical trial tested whether adding the medication exenatide to insulin glargine helps manage blood sugar levels in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 261 people

Who can join Ages 18+ · all sexes

Timeline Started 2008-10 · est. completion 2010-01

Where 59 sites · Greece, Israel, Mexico, Puerto Rico, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT00765817 ↗

Description as written by the study sponsor.

This study will compare the efficacy and safety of exenatide versus placebo in adults whose diabetes is not fully controlled by insulin glargine with or without metformin and/or pioglitazone.

Treatments tested

placebo Drug

subcutaneous injection, twice a day
exenatide Drug

subcutaneous injection, twice a day, 10mcg

Main thing measured	Change in Glycosylated Hemoglobin (HbA1c)
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00765817 ↗